63991-67-3

Basic information

• Product Name: (4-benzylpiperazin-1-yl)(phenyl)methanone
• Synonyms: (4-Benzyl-piperazin-1-yl)-phenyl-methanone; methanone, phenyl[4-(phenylmethyl)-1-piperazinyl]-
• CAS NO: 63991-67-3
• Molecular Formula: C₁₈H₂₀N₂O
• Molecular Weight: 280.3642
• Mol File: 63991-67-3.mol
• Article Data: 13

Chemical Properties

• Boiling Point: 427.2°C at 760 mmHg
• Flash Point: 182.3°C
• Density: 1.149g/cm³
• Vapor Pressure: 1.67E-07mmHg at 25°C
• Refractive Index: 1.608
• CAS DataBase Reference: (4-benzylpiperazin-1-yl)(phenyl)methanone(CAS DataBase Reference)
• NIST Chemistry Reference: (4-benzylpiperazin-1-yl)(phenyl)methanone(63991-67-3)
• EPA Substance Registry System: (4-benzylpiperazin-1-yl)(phenyl)methanone(63991-67-3)

Safety Data

• Hazardous Substances Data: 63991-67-3(Hazardous Substances Data)

Upstream product

• 2759-28-6 1-phenylmethylpiperazine 
• 98-88-4 benzoyl chloride 
• 110-85-0 piperazine 
• 100-39-0 benzyl bromide 
• 100-52-7 benzaldehyde 
• 13754-38-6 N-Benzoylpiperazine 
• 55-21-0 benzamide 
• 611-73-4 Benzoylformic acid 
• 6091-41-4 1,4-dibenzoylpiperazine 
• 148120-38-1 1-(phenylmethyl)-4-[(4'-methoxyphenyl)methyl]piperazine 
• 2803-00-1 N-trifluoroacetyl,N-benzyl piperazine 
• 25804-49-3 tert-butyl 4-hydroxybenzoate 
• 100-44-7 benzyl chloride 
• 2902-69-4 2,2,2-trichloroacetophenone 

Downstream Products

• 385381-49-7 [4-(4-fluoro-benzenesulfonyl)-piperazin-1-yl]-phenyl-methanone 
• 13754-38-6 N-Benzoylpiperazine 

Relevant articles and documents

Hydrosilylative reduction of primary amides to primary amines catalyzed by a terminal [Ni-OH] complex

A terminal [Ni-OH] complex1, supported by triflamide-functionalized NHC ligands, catalyzes the hydrosilylative reduction of a range of primary amides into primary amines in good to excellent yields under base-free conditions with key functional group tolerance. Catalyst1is also effective for the reduction of a variety of tertiary and secondary amides. In contrast to literature reports, the reactivity of1towards amide reduction follows an inverse trend,i.e., 1° amide > 3° amide > 2° amide. The reaction does not follow a usual dehydration pathway.

GPR52 Antagonist Reduces Huntingtin Levels and Ameliorates Huntington's Disease-Related Phenotypes

GPR52 is an orphan G protein-coupled receptor (GPCR) that has been recently implicated as a potential drug target of Huntington's disease (HD), an incurable monogenic neurodegenerative disorder. In this research, we found that striatal knockdown of GPR52 reduces mHTT levels in adult HdhQ140 mice, validating GPR52 as an HD target. In addition, we discovered a highly potent and specific GPR52 antagonist Comp-43 with an IC50 value of 0.63 μM by a structure-activity relationship (SAR) study. Further studies showed that Comp-43 reduces mHTT levels by targeting GPR52 and promotes survival of mouse primary striatal neurons. Moreover, in vivo study showed that Comp-43 not only reduces mHTT levels but also rescues HD-related phenotypes in HdhQ140 mice. Taken together, our study confirms that inhibition of GPR52 is a promising strategy for HD therapy, and the GPR52 antagonist Comp-43 might serve as a lead compound for further investigation.

Mesoporous niobium oxide spheres as an effective catalyst for the transamidation of primary amides with amines

Mesoporous niobium oxide spheres (MNOS), conveniently prepared by a novel antisolvent precipitation approach, have been shown to be an effective catalyst for the transamidation of primary amides with amines. This novel transamidation can be efficiently carried out under solvent-free conditions and is applicable to a wide range of primary amides and amines to provide N-alkyl amides in good to excellent yields. The catalyst is highly stable and reusable. The application of this transamidation reaction has been demonstrated in the synthesis of antidepressant drug moclobemide and other druglike compounds.